SSTR2 and neoplasm: PSC-PEG2-TOC (VMT-α-NET) is a novel somatostatin receptor subtype 2 (SSTR2) targeting peptide for the treatment of neuroendocrine tumors (NET) that shows rapid tumor accumulation, high tumor retention, and fast renal excretion with the potential for low nephrotoxicity [6, 7].